MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Polyinosinic-polycytidylic acid

MCE 國際站：Polyinosinic-polycytidylic acid

品牌：MedChemExpress (MCE)

CAS：24939-03-5

貨號：HY-107202

Synonyms：Poly(I:C

存儲條件：粉末 -20°C 3 年 溶劑中 -80°C 6 個月 -20°C 1 個月

運輸條件：美國大陸的室溫；其他地方可能有所不同。

產品活性：Polyinosinic-polycytidylic acid (Poly(I:C)) 是雙鏈 RNA 的合成類似物，是一種 TLR3 和視黃酸誘導型基因 I 受體 (RIG-I 和 MDA5) 的激動劑。Polyinosinic-polycytidylic acid 可以用作疫苗佐劑，以增強先天性和適應性免疫反應，并改變腫瘤的微環境，還可以直接觸發癌細胞發生凋亡 (apoptosis)。

體外：Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) 呈現劑量和時間依賴性增加誘導永生化氣道上皮細胞的細胞旁通透性[4]。 Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) 對 16HBE14o- 細胞沒有細胞毒性[4]。 Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) 在 16HBE14o- 細胞中誘導上皮頂端連接復合體和緊密連接的破壞[4]。 MCE尚未獨立證實這些方法的準確性。僅供參考。

體內：Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) 在腦黑質和背外側紋狀體中誘導持續的炎癥反應[2]。 Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) 降低小鼠的肺腫瘤生長[3]。 Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) 在 MCAO 模型小鼠中通過 TLR3 下調TLR4/MyD88 信號通路發揮腦缺血再灌注損傷的治療作用[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50 & Target：Bcl-2 Bax IL-17A IL-13 HSP70

銷售產品：Exatecan (mesylate)  | MRTX1133  | Cetuximab  | MG-132  | SBE-β-CD  | Rapamycin  | Tamoxifen  | Olaparib  | Sotorasib  | Eribulin (mesylate)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [2]. Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. [3]. Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223.[4]. Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101.[5]. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364.[6]. Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11.[7]. Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.